PMID- 36986665
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230331
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 15
IP  - 3
DP  - 2023 Mar 1
TI  - Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old 
      Drugs, a Step Forward in the Safety Profile?
LID - 10.3390/pharmaceutics15030804 [doi]
LID - 804
AB  - Antibacterial fluoroquinolones (FQs) are frequently used in treating infections. 
      However, the value of FQs is debatable due to their association with severe 
      adverse effects (AEs). The Food and Drug Administration (FDA) issued safety 
      warnings concerning their side-effects in 2008, followed by the European Medicine 
      Agency (EMA) and regulatory authorities from other countries. Severe AEs 
      associated with some FQs have been reported, leading to their withdrawal from the 
      market. New systemic FQs have been recently approved. The FDA and EMA approved 
      delafloxacin. Additionally, lascufloxacin, levonadifloxacin, nemonoxacin, 
      sitafloxacin, and zabofloxacin were approved in their origin countries. The 
      relevant AEs of FQs and their mechanisms of occurrence have been approached. New 
      systemic FQs present potent antibacterial activity against many resistant 
      bacteria (including resistance to FQs). Generally, in clinical studies, the new 
      FQs were well-tolerated with mild or moderate AEs. All the new FQs approved in 
      the origin countries require more clinical studies to meet FDA or EMA 
      requirements. Post-marketing surveillance will confirm or infirm the known safety 
      profile of these new antibacterial drugs. The main AEs of the FQs class were 
      addressed, highlighting the existing data for the recently approved ones. In 
      addition, the general management of AEs when they occur and the rational use and 
      caution of modern FQs were outlined.
FAU - Rusu, Aura
AU  - Rusu A
AUID- ORCID: 0000-0003-4979-6903
AD  - Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, 
      George Emil Palade University of Medicine, Pharmacy, Science, and Technology of 
      Targu Mures, 540142 Targu Mures, Romania.
FAU - Munteanu, Alexandra-Cristina
AU  - Munteanu AC
AUID- ORCID: 0000-0003-1281-3749
AD  - Department of General and Inorganic Chemistry, Faculty of Pharmacy, Carol Davila 
      University of Medicine and Pharmacy, 6 Traian Vuia Str., 020956 Bucharest, 
      Romania.
FAU - Arbanasi, Eliza-Mihaela
AU  - Arbanasi EM
AD  - Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, 
      George Emil Palade University of Medicine, Pharmacy, Science, and Technology of 
      Targu Mures, 540142 Targu Mures, Romania.
FAU - Uivarosi, Valentina
AU  - Uivarosi V
AUID- ORCID: 0000-0002-7165-5069
AD  - Department of General and Inorganic Chemistry, Faculty of Pharmacy, Carol Davila 
      University of Medicine and Pharmacy, 6 Traian Vuia Str., 020956 Bucharest, 
      Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230301
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC10056716
OTO - NOTNLM
OT  - adverse effects
OT  - antibacterial quinolones
OT  - delafloxacin
OT  - fluoroquinolones
OT  - lascufloxacin
OT  - levonadifloxacin
OT  - nemonoxacin
OT  - side-effects
OT  - sitafloxacin
OT  - zabofloxacin
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/30 06:01
PMCR- 2023/03/01
CRDT- 2023/03/29 02:02
PHST- 2022/11/27 00:00 [received]
PHST- 2023/02/07 00:00 [revised]
PHST- 2023/02/17 00:00 [accepted]
PHST- 2023/03/30 06:01 [medline]
PHST- 2023/03/29 02:02 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/03/01 00:00 [pmc-release]
AID - pharmaceutics15030804 [pii]
AID - pharmaceutics-15-00804 [pii]
AID - 10.3390/pharmaceutics15030804 [doi]
PST - epublish
SO  - Pharmaceutics. 2023 Mar 1;15(3):804. doi: 10.3390/pharmaceutics15030804.